RENAL CELL CARCINOMA
Clinical trials for RENAL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RENAL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RENAL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
First human test of experimental cancer drug begins
Disease control TerminatedThis early-stage study tested a new cancer drug called PF-07820435, both alone and combined with an existing immunotherapy drug (sasanlimab), in people with advanced solid tumors. The main goals were to find safe doses and look for early signs that the treatment might help shrink…
Matched conditions: RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Apr 01, 2026 18:41 UTC
-
Drug duo tested to fight cancer that spread to the brain
Disease control TerminatedThis study tested whether a combination of two drugs, pembrolizumab and lenvatinib, could shrink tumors in the brain for patients with melanoma or kidney cancer that had spread there. The trial was for patients whose cancer had worsened despite previous immunotherapy. The main go…
Matched conditions: RENAL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New pill tested for Tough-to-Treat kidney cancer
Disease control TerminatedThis study tested a new oral pill called NKT2152 for adults with advanced kidney cancer that had stopped responding to standard treatments. The first part aimed to find a safe and effective dose. The second part planned to see how well the pill could shrink tumors and control the…
Matched conditions: RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
First human test of new cancer drug halted
Disease control TerminatedThis early-stage study aimed to find a safe dose of a new drug called HFB301001 for adults with advanced cancers that had stopped responding to standard treatments. It involved 31 patients with cancers like sarcoma, kidney, liver, and melanoma. The trial was designed to test incr…
Matched conditions: RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: HiFiBiO Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
First patients test new cancer drug in early safety trial
Disease control TerminatedThis was an early-stage study to test the safety and find the right dose of a new cancer drug called PF-07826390. It was given alone or combined with another immunotherapy drug to people with advanced solid tumors that had spread or stopped responding to treatment. The main goal …
Matched conditions: RENAL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New cancer drug trial halted after early testing
Disease control TerminatedThis early-stage study tested a new drug called OC-001, both by itself and combined with an existing immunotherapy drug, in people with various advanced cancers that had stopped responding to standard treatments. The main goal was to check the safety of the drug and see how the b…
Matched conditions: RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Ocellaris Pharma, Inc. • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Early trial halted for new cancer drug targeting multiple advanced cancers
Disease control TerminatedThis early-stage study tested a new drug called PRO1160 in 42 patients with advanced cancers that had spread or returned after previous treatments. The main goals were to find a safe dose and see if the drug could help control kidney cancer, nasopharyngeal cancer, or lymphoma. Th…
Matched conditions: RENAL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Mar 09, 2026 14:25 UTC
-
New scan could spot cancer treatment success in weeks, not months
Knowledge-focused TerminatedThis study tested a special type of MRI scan that doesn't require an injection of dye. The goal was to see if this scan could detect changes in blood flow to kidney cancer tumors very early in treatment, potentially showing if the therapy is working weeks before a standard scan c…
Matched conditions: RENAL CELL CARCINOMA
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Mar 24, 2026 12:02 UTC